These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28716728)

  • 1. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats.
    Qin X; Lu J; Wang P; Xu P; Liu M; Wang X
    Biochem Pharmacol; 2017 Nov; 143():129-139. PubMed ID: 28716728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
    Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
    J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
    Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research.
    Lu J; Shao Y; Qin X; Liu D; Chen A; Li D; Liu M; Wang X
    Sci Rep; 2017 Feb; 7():42922. PubMed ID: 28218310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
    Lee JH; Lee A; Oh JH; Lee YJ
    Biopharm Drug Dispos; 2012 Nov; 33(8):474-86. PubMed ID: 22936118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
    Kim TH; Shin S; Kim S; Bulitta JB; Weon KY; Joo SH; Ma E; Yoo SD; Park GY; Kwon DR; Jeong SW; Lee DY; Shin BS
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28891960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
    Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.
    Deng S; Wang C; Zhang W; Gao W; Fan A; Zhang Q; Zhang Y; Liu Q; Li N; Liu Q; Zhao J; Li C; Wen X; Zhao D; Chen X
    Xenobiotica; 2014 Jul; 44(7):583-90. PubMed ID: 24329500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.
    Yang JZ; Song Y; Xiong JH; Lin YX; Wen C; Li Y; Zhou Y
    Biomed Res Int; 2021; 2021():6679082. PubMed ID: 34195278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
    Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
    Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
    Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
    Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
    Foo WY; Tay HY; Chan EC; Lau AJ
    Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.
    Rysz MA; Kinzi J; Schäfer AM; In-Albon K; Zürcher S; Schmidlin S; Seibert I; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
    J Pharm Biomed Anal; 2023 Nov; 236():115716. PubMed ID: 37722165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
    Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
    Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
    Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions.
    Lee JH; Shin YJ; Kim HJ; Oh JH; Jang YP; Lee YJ
    Int J Pharm; 2011 May; 410(1-2):68-74. PubMed ID: 21421030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
    Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
    J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
    O'Malley M; King AN; Conte M; Ellingrod VL; Ramnath N
    J Thorac Oncol; 2014 Jul; 9(7):917-926. PubMed ID: 24926542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.